COVID-19 Update

COVID-19 has imposed an unsettling situation upon our community and our business, but at Cleveland Diabetes Care and our affiliates, KRS Global Biotechnology and Complete Pharmacy Medical Solutions, we are committed to fighting back the best way we know how. By providing better medicine for better lives we will continue operations that include creation and distribution of life saving medications and testing kits to all reaches of our great nation.

Category Archives:
503b Compounding

29

September
2014

category:

503b Compounding

FDA: Eye drops recalled over flawed production

THE Food and Drug Administration (FDA) announced Thursday the voluntary recall of a particular batch of Antazoline Hydrochloride/Tetryzoline Hydrochloride (Spersallerg) 500mcg/400mcg/ per mL Ophthalmic Solution (Drops) owing to its supposed failure to meet Good Manufacturing Practice (GMP). According to FDA Advisory No. 2014-071, Novartis Healthcare Philippines Inc. ordered the recall of the product’s Batch No. […]

read more

24

September
2014

category:

503b Compounding

Pharmacies banned from compounding for docs without prescription

The US Food and Drug Administration (FDA) says compounding pharmacies must not manufacture medicines for hospitals and doctors’ offices, except for named patients. http://www.in-pharmatechnologist.com/Regulatory-Safety/Pharmacies-banned-from-compounding-for-docs-without-prescription

read more

23

September
2014

category:

503b Compounding

Are Generic Drugs Dangerous?

Generic drugs have long been pushed on American consumers as cost-effective alternatives to brand-name prescription medicines. But widespread manufacturing irregularities at drug factories overseas are raising troubling new questions about the safety of generics and whether they are putting Americans’ health at risk.  A new analysis by the U.S. National Bureau of Economic Research reveals […]

read more